Select Page
Responsive Centered YouTube Video
Concerns raised about potential cover-up of excess deaths through misleading tactics and vaccine safety issues.
  • Early concerns about rushing vaccines and potential safety risks highlighted by Professor Hotes. 0:52

  • Warning about unique safety problems of coronavirus vaccines and immune enhancement phenomenon. 2:03

  • Observation of immune pathology in animal models from coronavirus vaccines development. 3:41

Investigation into excess mortality rates in Western countries raises concerns about potential cover-ups.
  • Excess mortality rates in highly vaccinated regions like the UK and US are a cause for concern. 4:13

  • Bulgaria, with lower vaccination rates, shows lower excess mortality rates compared to highly vaccinated countries. 5:09

  • Calls for investigations into excess deaths are being ignored in countries like Australia and the UK. 7:01

  • Historical information from 2004 reveals scrutiny of emails from pharmaceutical company Merck. 7:52

Uncovering potential cover-up of excess deaths due to vaccine risks and financial interests.
  • Vioxx, a non-steroidal anti-inflammatory drug, was pulled off the market by Merck due to safety concerns. 8:22

  • Merck had to pay a settlement of 4.85 billion in 2007 for Vioxx-related issues. 9:04

  • Concerns raised about excess deaths possibly linked to vaccines and the need for serious investigation. 10:07

  • Autopsy and histological examination of tissue are crucial to identify causes of excess deaths. 11:05

  • Financial interests may hinder a thorough investigation into excess deaths. 11:35

  • Urgent push needed for a comprehensive investigation to ensure public safety. 11:58

  • Warning against fast-tracking vaccines without proper evaluation. 12:21

Analysis of vaccine communication plan, potential need for third immunization, and impact on virus transmission.
  • Communication plan for covid-19 vaccines and trusted spokesperson discussed. 12:59

  • Emergency use authorization for vaccines explained and importance of getting vaccinated. 13:22

  • Duration and effectiveness of two-dose vaccines in preventing viral transmission. 13:37

  • Estimation of population vaccination thresholds to halt virus transmission. 14:33

  • Importance of achieving high vaccination rates to interrupt virus transmission. 14:47

  • Prediction of potential need for a third immunization with mRNA vaccines. 14:54

  • Discussion on the necessity of a third immunization for complete protection. 15:00

Challenges with defining full vaccination and concerns over potential future vaccine requirements.
  • Shifting goalposts in defining full vaccination to include booster doses. 15:56

  • Potential need for regular booster shots, possibly twice yearly. 16:44

  • Concerns over silence and lack of acknowledgment of potential issues. 17:14

  • Warning about the consequences of ignoring discrepancies in vaccination data. 17:21

  • Highlighting the importance of observing, anticipating, and addressing future challenges. 17:43

  • Fear of desperate measures to cover up problems that should be addressed. 17:50

  • Emphasis on the potential impact on lives if issues are not acknowledged and addressed. 17:59